These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 1299984)

  • 21. Profile of medication identification requests managed by a U.S.-certified regional poison information center.
    Krenzelok EP; Mrvos R
    Clin Toxicol (Phila); 2009 Apr; 47(4):364-5. PubMed ID: 19365774
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Drug-induced parkinsonian syndromes: a 10-year experience at a regional center of pharmaco-vigilance].
    Llau ME; Nguyen L; Senard JM; Rascol O; Montastruc JL
    Rev Neurol (Paris); 1994 Nov; 150(11):757-62. PubMed ID: 7597368
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug information centers: ASHP's role and effect of clinical pharmacy.
    Walton CA; Knodel LC
    Am J Hosp Pharm; 1983 Jul; 40(7):1217-8. PubMed ID: 6881164
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Pharmacovigilance as new direction of research].
    Gaszner G; Makkos Z; Gaszner P
    Neuropsychopharmacol Hung; 2005 Dec; 7(4):194-8. PubMed ID: 16496484
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Analysis of toxicological information rendered by the staff of the National Poison Information Center and physicians at the Clinic of Acute Poisoning of the Institute of Occupational Medicine in Lódź].
    Jaraczewska W; Czerczak S; Kotwica M; Jarosz A
    Przegl Lek; 1996; 53(8):595-9. PubMed ID: 8999459
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Financial analysis of hospitalizations for adverse effects of drugs. The economic role of the Regional Pharmacovigilance Center].
    Mignot G; Biaggi J; Lethurgez P; Chichmanian RM
    Therapie; 1990; 45(5):387-90. PubMed ID: 2260030
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacovigilance of antimalarial treatment in Uganda: community perceptions and suggestions for reporting adverse events.
    Bukirwa H; Nayiga S; Lubanga R; Mwebaza N; Chandler C; Hopkins H; Talisuna AO; Staedke SG
    Trop Med Int Health; 2008 Sep; 13(9):1143-52. PubMed ID: 18631312
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Essential, economic and social significance of the Poison Information Center for public health].
    Panas M; Targosz D; Motyka E; Szkolnicka B
    Przegl Lek; 1997; 54(6):477-80. PubMed ID: 9333908
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Organization and results of drug vigilance in France].
    Bégaud B; Chaslerie A; Haramburu F
    Rev Epidemiol Sante Publique; 1994; 42(5):416-23. PubMed ID: 7973001
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A profile of calls to a poison information center regarding older adults.
    Skarupski KA; Mrvos R; Krenzelok EP
    J Aging Health; 2004; 16(2):228-47. PubMed ID: 15030664
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Responsibility of poison control center physicians].
    Bonny JS; Breurec JY; Baert A; Develay-Le Gueut M; Curtes JP
    J Toxicol Clin Exp; 1989; 9(3):197-203. PubMed ID: 2593094
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Adverse drug effects observed at French admissions departments and emergency services (Prospective study of the National Educational Association for Teaching Therapeutics and proposals for preventive measures].
    Queneau P; Bannwarth B; Carpentier F; Guliana JM; Bouget J; Trombert B; Leverve X;
    Bull Acad Natl Med; 2003; 187(4):647-66; discussion 666-70. PubMed ID: 14556474
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Poison Control and the Drug Information Center: the Palestinian experience.
    Sawalha AF
    Isr Med Assoc J; 2008 Nov; 10(11):757-60. PubMed ID: 19070281
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Development and perspectives of community DOTS].
    Narita T; Kobayashi N
    Kekkaku; 2009 Apr; 84(4):187-201. PubMed ID: 19425394
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Isotretinoin in childbearing women: compliance with strengthen warnings].
    Autret-Leca E; Jonville-Béra AP; Szafir D; Cissoko H; Boulkroun Y; Goehrs JM
    Ann Dermatol Venereol; 2000 Oct; 127(10):808-13. PubMed ID: 11060382
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of US poison centers in adverse drug reactions monitoring.
    Chyka PA
    Vet Hum Toxicol; 1999 Dec; 41(6):400-2. PubMed ID: 10592954
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nationwide survey of subjectively reported adverse drug reactions in Sweden.
    Isacson D; Johansson L; Bingefors K
    Ann Pharmacother; 2008 Mar; 42(3):347-53. PubMed ID: 18303136
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Evaluation of reports on "pregnancy and drugs" received during a period of 39 months by the Regional Pharmacovigilance Center, Lorraine (Nancy)].
    Hanesse B; Trechot P; el Kouch S; Pierfitte C; Royer R; Netter P
    Therapie; 1995; 50(5):471-2. PubMed ID: 8571291
    [No Abstract]   [Full Text] [Related]  

  • 39. Adult glyburide ingestions reported to Texas poison control centers, 1998 2005.
    Forrester MB
    Hum Exp Toxicol; 2007 Jul; 26(7):563-71. PubMed ID: 17884959
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systemic adverse drug reactions: a preliminary report from the regional pharmacovigilance center, western Nepal.
    P S; P M; Pr S
    Pak J Pharm Sci; 2008 Oct; 21(4):465-7. PubMed ID: 18930872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.